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Antimicrobial  defense  mechanisms  are  enhanced  by  antigen-specific  T  cell 
differentiation followed by activation of mononuclear phagocytes (1, 2). 3" Inter- 
feron  (IFN-3,) ~ is  an  important  mediator  of  both  antimicrobial  activity  and 
hydrogen  peroxide  secretion  in  mononuclear  phagocytes  (3).  A  number  of 
observations suggest that an immunological defect exists in lepromatous leprosy 
w_hich-allows the extensive replication of M.  leprae within dermal macrophages 
(4). The skin lesions are relatively deprived of helper T  cells (OKT4), which are 
an important source of IFN-3" (5-7). The exposure of peripheral blood T  cells 
to M.  leprae  fails to result  in  appreciable  T  cell proliferation and  synthesis  of 
lymphokine,  including  IFN-3" (8-10).  In  contrast,  the  lymphocytes of patients 
with lepromatous leprosy can respond to l~ctins and other antigens to which they 
are  sensitized  (4,  8-13).  This  had  lead  to  the  concept of selective anergy  in 
which, either due to the absence ofM. leprae-reactive T  cells and/or the activity 
of suppressor cells or factors, macrophage activation does not occur and microbial 
dissemination ensues (1 1-23). 
In  the  course  of studies  on  the  reversal  of T  cell  nonresponsiveness  with 
purified IL-2 in lepromatous leprosy patients (8), we were struck by the hetero- 
geneous response to this T  cell growth factor. We have therefore reexamined 
the responsiveness of T  cells to M. leprae and other antigens, and evaluated their 
stimulation by recombinant IL-2 and their possible inhibition by suppressor cell 
populations. 
Materials and Methods 
Patients.  Patients (see Table I) were seen in New York at the regional Hansen's Disease 
Center, Baley Seton Hospital, Staten Island, or at the Frederico Lleras Acosta Hospital 
de Dermatologia, Bogota, Colombia. The clinical diagnosis of leprosy was supported in 
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all patients by a skin biopsy which was examined by Dr. Job at the U. S.  Public Health 
Service, National Hansen's Disease  Center, Carville, LA, and diagnosed by the Ridley 
Jopling classification (24). 
Mononuclear cells.  Cell-mediated immunity in vitro was assessed  in bulk blood mono- 
nuclear cells  (9),  or  in  populations that  were  depleted of monocytes, T  cells,  and  B 
lymphocytes. Monoclonal antibodies (mAb) against monocytes (3C10), B cells (BA-1), T 
helper cells (OKT4), T  suppressor/cytotoxic cells (OKT8), and rabbit complement (C*) 
were used to deplete defined subpopulations of leukocytes (25-27). Controls were treated 
with C* only. Monocyte elimination was monitored by cytology, staining for nonspecific 
esterase, or immunofluorescent staining for residual 3C 10; T  cell subset elimination by 
staining for residual OKT4 or OKT8 antigen; B cell depletion by staining with fluorescent 
goat anti-human Ig. 
Antigen Stimulation of Lymphocytes.  Mononuclear cells were plated in triplicate at 1.5 
x  105 cells  per well in  96-well, round-bottom plates in  200  ILl of RPMI  1640 (Gibco 
Laboratories, Grand Island, NY) supplemented with 10% human AB+ serum, 100 U/ml 
penicillin,  1 t~g/ml streptomycin, and 2 mM glutamine. Armadillo-derived, freeze-dried 
M. leprae antigen was obtained from Dr. R.J.W.  Rees (IMMLEP Bank), The National 
Institute of Medical Research, Mill Hill, England, and was added to the cultures at 8 ~g/ 
well. Heat-killed bacillus Calmette-Guerin (BCG) (The Trudeau Institute, Saranac Lake, 
NY) was added at 2 x  104 bacteria per well. At the end of 5 d, 75-100 ~1 of supernatant 
was removed from each well to quantitate IFN-3, levels, and 1 #Ci [~H]thymidine (Schwarz 
Mann Div., Becton, Dickinson & Co., Orangeburg, NY) was added (5 #Ci/mi). After an 
additional 16 h, [SH]thymidine uptake was assessed. To evaluate the statistical  significance 
of changes in cell proliferation, the paired comparisons t test was used. 
Mitogen Stimulation.  Cells were plated as above except that 96-well flat-bottom plates 
were used, proliferation was monitored at 72 h, and concanavalin A (Con A) was added 
at 2 #g/ml. 
Effects of Exogenous IL-2.  Recombinant IL-2 (rIL-2) (the generous gift of Dr.  Seth 
Rudnick; sp act, 8.5 X 10 s U/mg; Biogen Research Corp., Cambridge, MA) was added at 
the  onset  at  3  U/well  with  and  without M.  leprae or  BCG.  T  cell  proliferation was 
measured at  day 6.  In  other studies,  1.5  U  was  added  every 24  h  (5  times) and  the 
proliferative responses were evaluated daily. The dose of IL-2 corresponded to a dose 
that moderately enhanced background T cell proliferation in the absence of mycobacteria 
(see Results),  so that synergy between 1L-2 and antigen could be detected. 
Radioimmunoassay for  IFN-%  The  amount  of IFN-3,  in  the  culture  medium  was 
determined  with  an  assay  kit  (IMRX  Corp.,  Centocor  Malvern,  PA).  Samples  were 
incubated with polystyrene beads coated with a mouse monoclonal anti-IFN-~' antibody, 
washed, and incubated with a  125I-labeled second mouse anti-IFN-3,  mAb directed to an 
epitope distinct from that  recognized by the first mAb.  The amount of IFN-3,  in the 
supernatant was estimated by comparison with a standard curve generated with purified 
IFN-7. The limit of detection was 0.1-0.2 U/ml. 
Results 
The  pertinent  information  including  diagnosis,  bacterial  loads,  country  of 
origin,  and  therapy  of  32  unselected  patients  is  summarized  in  Table  I.  In 
subsequent tables, only the corresponding patient number will be used. 
Proliferative  Responses to Antigen and to Mitogen.  Mononuclear leukocytes from 
patients were cultured in the presence or absence of antigen (M. leprae,  BCG) or 
mitogen  (Con  A),  and  their  proliferative  response  evaluated  (Table  II).  The 
ability  to  respond  to  M.  leprae  varied  widely.  In  addition  to  the  previously 
reported differences between the lepromatous and tuberculoid forms of leprosy 
(4, 9, 11), the lepromatous leprosy and (LL and BL) patients fell into two groups. 
14  of 26  were nonresponders  to M.  leprae  (group A,  Table  I);  i.e.,  the  mean 
stimulation  index  was  1.5  relative to the  no antigen  control and  the  absolute KAPLAN  ET  AL. 
TABLE  I 
Pertinent Demographic Diagnostic and Therapeutic Information of Leprosy Patients 
Age  Bacterial in-  Treatment (time, drugs)  Patient No.  (years)  Sex  National origin  Diagnosis  dex 
919 
1  ,5.5  F  Colombia  LL  4+  None 
2  32  M  Colombia  LL  3-6+  None 
3  59  M  Caribbean  LL  1  +  5 yr (DDS 10O; B663200) 
4  36  M  Caribbean  LL  5+  1 yr (DDS100;  RIF60O) 
5  30  M  Guyana  LL  6+  1.5 yr (DDS100; RIF600) 
6  68  M  Venezuela  LL  4+**  15 yr (DDS irregular) 
7  55  F  Colombia  LL  6+  4 yr (DDS irregular) 
8  64  M  Colombia  BL  3+  3 yr (DDSIO0; RIF60O; ThallO0) 
9  30  M  Grenada  LL (ENL)  5+  2 yr (DDS100;  RIF600; Tball00) 
10  36  M  Mexico  LL  4+  4 yr (DDSI00; RIF600) 
11  41  M  Colombia  LL  3-6+  3 mo (DDS 100; RI  F600) 
12  31  M  Colombia  LL  4+  1 mo (DDSI00; RIF600; LAMP600) 
13  32  M  Greece  LL  1+  8 yr (DDS100) 
14  27  F  Santo Domingo  LL  6+  None 
15  30  F  Caribbean  LL (ENL)  --  5 yr (B663100;  Thall0O) 
16  49  M  Vietnam  LL  3+  3 yr (B663100;  Thai200) 
17  35  F  Vietnam  BL/BB  4+  None 
18  27  M  Colombia  LL  6+  3 yr (DDSI00; RIF600) 
19  33  M  China  LL  --  5 yr (DDS100;  RIF600) 
20  32  M  Puerto Rico  LL (inact.)  --  7 yr (DDS100) 
21  38  F  Trinidad  BL  2+  4 yr (DDS100) 
22  37  M  Santo Domingo  LL  6+  10 yr (DDSI00) 
23  78  M  Caribbean  LL (inact.)  --  6 yr (DDS 100; RIF60O) 
24  41  F  Trinidad  LL  1  +  14 yr (DDS 100) 
25  51  M  Caribbean  LL  --  19 yr (DDSI0O; RIF600) 
26  33  M  Venezuela  BL  5+  2 mo (DDS100;  RIF600) 
27  44  M  Colombia  BT  --  None 
28  8  M  Colombia  BL/BB  1+  None 
29  60  F  Caribbean  BT  --  1 yr (DDSIO0) 
30  50  M  China  BT (N)  --  >5 yr (DDS10O; RIF600) 
31  35  M  Ghana  BT (N)  --  10 yr (DDS 10O) 
32  23  F  Philippines  BT  --  3 yr (DDS 100) 
Pertinent  demographic  and diagnostic  information  based on the Ridley-Jopling  classification  (22).  LL, lepromatous leprosy;  BL, 
borderline  lepromatous;  BB, mid-borderline; BT, borderline  tuberculoid.  Two patients  had erythema  nodosum  leprosum (ENL) 
(Nos. 9, ] 5) at the time of the study~  Patients 20 and 23 were inactive.  Two patients had neural symptoms  (N) (Nos. 30, 31 ). DDS, 
dapsone;  RIF, rifampin; B663, clofazimine;  Thai, tbaliodmide; LAMP, lamprin. The number following  the drug denotes the dose 
in mg/d. 
* DDS resistant. 
proliferation  was  <1,500  cpm.  The  other  12  patients  exhibited  low  levels  of 
proliferation (group B, mean stimulation index of 6.1). A third group of patients 
(mid-borderline  leprosy  [BB] and borderline  tuberculoid  [BT]) responded  vig- 
orously (group C, Table  I). The nonresponder and low responder patients with 
lepromatous leprosy could not otherwise be distinguished on the basis of histo- 
pathologic classification, bacterial indices, or the duration and type of treatment 
(Table  I).  When  cells from lepromatous patients were tested for BCG-induced 
proliferation, 5 of 11  nonresponders (Nos. 6,  11,  12,  13, and  14) and 4 of 7 low 
responders (Nos.  18,  19,  22,  25) reacted.  This confirms previous reports (11- 
13) on the presence of a  BCG-reactive  T  cell population  in patients unable to 
respond to M. leprae.  T  cells from all patients proliferated in response to Con A 
as reported  (9).  Therefore,  the T  cell defect in  lepromatous disease  is specific 
for M. leprae but is manifested as both nonresponsive and hyporesponsive states. 
Release of lFN-~, in Response  to Antigen or Mitogen.  The release of IFN-3, was 
used as an additional measure of T  cell function. Patients classified as M.  leprae 
nonresponders,  based  on  antigen-induced  proliferation,  also  failed  to  release TABLE  II 
Proliferative Response  to M. leprae, BCG, and Con A: Effect of Exogenous  IL-2 
Proliferative response (cpm x  10  -s [SH]thymidine) to: 
Response to M.  Patient  Mitogen  Antigen  IL-2 plus: 
leprae  No. 
M.  M.  No 
Con A  None  leprae  BCG  None  leprae  BCG  Ag 
Nonresponders 
Low responders 
Responders 
1  27.1  0.4  0.6  0.8  0.5  5.4  3.8  4.4 
2  37.1  1.5  1.3  2.2  0.6  3.0  2.9  1.7 
3  77.9  0.2  1.1  3.4  0.4  4.3  5.4  2.5 
4  18.9  1.8  0.8  NT  0.9  NT  NT  NT 
5  81.8  0.3  0.9  3.3  0.9  5.2  5.7  7.3 
6  46.5  0.9  0.6  10.0"  0.9  1.8  1.3"  5.7 
7  36.0  0.5  3.0  5.2  1.5  20.6  28.0  15.0 
8  11.0  1.7  2.1  NT  1.9  14.5  NT  6.4 
9  13.6  1.7  2.5  NT  1.9  12.5  NT  6.0 
10  49.9  0.9  1.4  2.9  1.1  15.9  17.6  3.2 
11  89.6  0.4  1.5  8.4*  0.7  12.0  21.3"  10.7 
12  75.7  1.1  2.9  33.9*  2.1  10.7  36.1"  5.5 
13  50.7  0.5  2.0  21.3"  0.8  15.4  NT  8.4 
14  85.7  1.1  0.7  5.8*  0.7  7.5  NT  6.2 
Mean SI  105  --  1.5  3.9 
(SD)  (108)  (0.6)  (2.4) 
14.4" 
(6.4)* 
15  11.2  1.0  3.5  NT 
16  48.2  2.1  4.7  NT 
17  8.1  1.0  4.4  4.6 
18  99.2  1.0  5.0  9.1" 
19  75.5  1.7  6.5  30.0* 
20  41.0  0.5  5.1  4.3 
21  NT  NT  6.1  NT 
22  106.6  0.8  5.1  70.1" 
23  41.I  0.5  5.1  4.3 
24  NT  NT  6.1  NT 
25  118.8  0.9  6.8  18.1" 
26  47.7  0.5  8.5  6.0* 
Mean SI  71.1  --  6.1  6.6 
(SD)  (44.3)  (2.9)  (5.2) 
28.8* 
(20.9)* 
0.3  NT  NT  NT 
2.4  NT  NT  NT 
0.7  4.4  NT  1.7 
0.9  13.6  15.5"  7.7 
2.0  15.5  28.3*  15.9 
1.5  6.3  NT  3.4 
0.7  11.5  NT  2.5 
1.2  7. t  NT  4.4 
1.5  6.3  NT  3.4 
0.7  11.6  NT  2.5 
0.7  10.2  NT  4.3 
1.2  16.3  11.4*  7.2 
27  36.5  0.8  15.9  NT  6.3  NT  NT  NT 
28  25.1  0.6  24.6  15.4"  1.0  32.2  28.2*  16.2 
29  24.5  1.8  26.4  NT  0.5  NT  NT  NT 
30  42.5  1.2  27.7  13.8"  1.1  31.4  NT  2.6 
31  53.9  1.3  49.7  27.3*  1.3  56.6  NT  4.3 
32  13.6  2.0  29.2  NT  0.9  NT  NT  NT 
Mean SI  30.8  --  29.3  16.3" 
(SD)  (14.9)  (15.2)  (3.5)* 
Proliferative response to M. leprae, heat-killed BCG, and Con A. IL-2:3 U  rlL-2 were added to 
some cultures at the start of incubation. 
* Patients that gave a  proliferative response to BCG.  NT, not tested. Mean stimulation index (SI) 
and standard deviation (SD) are shown for each group. 
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IFN-3, when presented with M.  leprae.  In contrast, 4  of 8  low responders (Nos. 
18, 22,  25,  26) and all high responders (Nos.  28, 30, 31) released IFN-3, (Table 
III). Cells from patients that proliferatet~ to BCG also released IFN-3, in response 
to  this antigen. Con A  induced high  levels of IFN-3, release  from  most of the 
patients tested (Table III). Therefore, any proliferative response of the cells to 
antigen or mitogen was accompanied by the concomitant release of IFN-7. 
TABLE  III 
Effect of Antigen and Mitogen Stimulation on Release of IFN-'y 
Response to M. leprae  Patient No. 
Units IFN-3, produced in response to: 
No  M. leprae  BCG  Con A  antigen 
Nonresponders 
Low responders 
Responders 
1  0.1  I 1.4  88.0  1.3 
2  1.8  2.4  39.2  1.8 
5  0.7  5.2  140.0  1.5 
6  0.2  7.2*  21.8  0.2 
7  2.0  7.1  80.1  1.5 
8  2.6  NT  5.2  1.4 
10  2.7  5.0  160.0  2.3 
11  0.1  11.4"  137.0  1.4 
12  3.0  58.0*  520.0  1.8 
14  0.8  8.0*  150.0  0.5 
Mean SI  1.1  4.1  11.4 
(SD)  (0.5)  (2.6)  (97.0) 
23.0* 
(11.4)* 
17  0.1  4.6  2.2  2.2 
18  5.0  5.5  12.2  1.3 
19  2.7  NT  120.0  1.5 
22  29.0  150.0"  270.0  0.5 
23  0.2  NT  NT  1.0 
24  0.1  NT  NT  0.1 
25  24.0  97.0*  NT  0.5 
26  10.8  7.8*  167.0  1.2 
Mean SI  15.1  5.1  157.6 
(SD)  (22.2)  (0.5)  (223.0) 
170" 
(117.2)* 
28  15.0  10.4"  212.0  1.0 
30  31.0  48.8*  66.0  0.8 
31  175.0  182.0"  250.0  1.2 
Mean SI  66.5  74.3*  167.3 
(SD)  (56.9)  (58.5)*  (60.3) 
The results are expressed as mean units IFN-7 released (measured by a direct radioimmunoassay) 
and mean stimulation index (SI) and standard deviation (SD) for each group. 
NT, not tested. 
* Patients that respond to BCG (see Table II). The mean SI (SD) for all nonresponders to BCG was 
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FIOURE  1.  The effect of rlL-2 on proliferation in response to M. leprae, in nonresponder 
(I-I), low  responder  (~l), and  responder  (m) patients. The results are expressed as  mean 
stimulation index  +  standard  deviation (bar). 3  U  IL-2 added  at start  of culture  where 
indicated. 
Effect  of Exogenous  IL-2  on  Proliferation  and  IFN-'y  Release.  The  effect  of 
exogenous  IL-2  on  the  proliferative  response  to  antigen  and  mitogen  was 
examined. The addition of a single dose of 3 U  of rIL-2 at the beginning of the 
culture period resulted in a  2-15-fold increase in [3H]thymidine incorporation 
in all patients,  compared with the no antigen control (Table II and  Fig.  1).  In 
the majority of low or nonresponders tested (15/22),  the addition of IL-2 and 
M. leprae, or IL-2 and BCG, gave an additive response. Only in 4 patients (Table 
II,  Nos.  8-10,  13)  was  the  response  more than  the  sum  of the  individual M. 
leprae and IL-2 effects. 
To ensure that functional  IL-2 was available throughout the culture period, 
additional studies were performed in which IL-2 was added daily for 5 d. If the 
cells were from nonresponder patients, multiple additions of IL-2 did not enhance 
proliferation beyond the predicted additive responses to M. leprae and IL-2 only 
(not  shown).  However,  low  responder  patients  did  exhibit an  increase  in  the 
absolute response to M. leprae, measured by proliferation as well as IFN-3, release 
(Figs. 2, A and B). Under these conditions, the ratio of the response to M. leprae 
over background (4.2, 4.6,  5.1; mean, 4.6 +  0.4) was the same as that observed 
from M.  leprae and  IL-2 over IL-2 alone (5.8,  3.8,  3.4, respectively; mean,  4.5 
+  0.9). These data indicate that additional IL-2 does not restore T  cell function 
in nonresponders, but does drive further expansion ofM. leprae-specific T  cells 
in low responders. 
Effects of Monocyte Depletion  on Antigen and Mitogen  Responses.  We next ex- 
amined if the blood of lepromatous patients had suppressor cells that dampened 
the M.  leprae  response.  Suppressor  monocytes were considered first using  the 
mAb 3C 10 and C*. This reagent specifically depletes monocytes, but dendritic 
cells, an accessory cell for many T-dependent responses, are unaffected (28).  In 
most experiments, B cells were also depleted together with monocytes to ensure 
that we were evaluating a  T  cell-proliferative response.  The mAb elimination 
method  was  evaluated  with  BCG  as  antigen.  7  of 8  BCG  responders  showed 
significantly enhanced proliferation after monocyte depletion (Table IV,  foot- 
note *; 0.025 >  P >  0.01). In contrast, responses to Con A were almost uniformly KAPLAN  ET  AL.  923 
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FIGURE  2.  The effect of exogenous  IL-2  on proliferation (A) and  IFN-'), production (B). 
Results are for three low responder lepromatous patients (Nos. 22-24), and are expressed as 
cpm (A) and units IFN-3, (B). (A  A), (0-----0), (X  X) Cells incubated with M. leprae and 
1.5 U of rlL-2 added daily. (~), O,  ~), Cells incubated with M. leprae only. [AI, lil, I'x'l, Cells 
incubated with 1.5 U  IL-2 added daily but no antigen. &, O, x, Cells incubated without IL-2 
or antigen. When 7.5 U  were added at the start of culture, the results were similar to those 
with 1.5 U added daily (not shown). 
reduced  (Table  IV).  Therefore,  it  appears  that  monocytes  are  contributory 
accessory cells  in  mitogen  responses,  but  are  not  required  and  may  even  be 
suppressive in the BCG system. 
When responses to M. leprae  were studied in 3C 10 plus C*-treated leukocytes, 
only 1 of 8 nonresponders (Table IV, group A, No. 4) showed >50% enhance- 
ment over the C* control. In contrast, 4 of 5 low responders and all responders 
to M. leprae exhibited significantly increased proliferation when monocytes were 
depleted (0.05  >  P  >  0.025  and  0.025  >  P  >  0.01,  respectively) (Table  IV). 
These results indicate that monocyte depletion can enhance preexisting responses 
but seldom reverses nonresponsiveness. 
Monocyte depletion also enhanced IFN-3, production in response to antigens, 
including BCG in BCG-reactive patients (Table V, Nos. 2, 6,  I 1, 26, 28, 30, 31) 
and M. leprae in two low responders (Table V, Nos. 18, 26). No enhancement of 
IFN-'y release was observed when monocytes were eliminated from nonrespon- 
sive patients. 
To evaluate the possibility that monocytes could inhibit the response to IL-2, 
monocytes were depleted  and  then  exogenous rIL-2  was added  to  cells from 
nonresponder patients.  Exogenous rIL-2,  in the presence or absence of mono- 
cytes, did not significantly enhance M.  leprae-induced T  cell proliferation  (not 
shown). 
Effects of Depletion of T Cell Subsets, in Combination with Monocyte Depletion and 
Addition  of lL-2.  T  cell proliferation  was next monitored in cultures depleted 
of suppressor  T  cells (OKT8),  monocytes (3C10),  helper  T  cells (OKT4),  or 
monocytes and suppressor T  cells.  Depletion of OKT8 + cells had no effect on 
proliferation  to M.  leprae or to BCG in  nonresponder patients,  but did reduce 
the Con A response (Table VI). Combined depletion of monocytes and suppressor 
T  cells (3C10  plus  OKT8  plus  C*)  also had  no  effect on  the  response  to M. 
leprae. Depletion of OKT4  + T  cells ablated the proliferation induced by Con A 
or BCG. 
We also added  7.5 U  of exogenous rIL-2 to the OKT4 and OKT8 antibody 
and C*-treated  leukocytes (data not shown).  IL-2 did not restore responses to 924  IN  VITRO  T  CELL  RESPONSIVENESS  IN  LEPROMATOUS  LEPROSY 
TABLE  IV 
Effects of Monocyte Depletion on T Cell Proliferation in Leprosy 
Proliferative response  (cpm[SH]thymidine)  to: 
Percent 
Responses to M.  mono-  M. leprae  BCG 
leprae  Patient No.  cyte de- 
mAb +  mAb +  pletion  C*  C* 
C*  C* 
Con A  No antigen 
mAb +  mAb + 
C*  C* 
C*  C* 
~0f 
cpra  C* control 
Nonresponders  1  81  1,056  132 
2  71  1,251  101 
3  96  1,090  140 
4  NT  1,200  425 
6  97  720  81 
7  92  1,056  132 
11  91  1,548  141 
13  NT  2,228  193 
Mean SI  0.8  1.1 
(SD)  (0.3)  (0.8) 
P value  0.1 > P >  0.05 
Low responders  15  99  12,461  156 
16  NT  3,393  205 
17  99  2,980  67 
18  80  2,004  341 
26  NT  6,784  431 
Mean SI  3.6  9.5 
(SD)  (2.2)  (3.8) 
P value  0.05 > P >  0.025 
Responders  27  97  19,537  183 
28  94  28,863  102 
29  NT  26,823  164 
30  95  26,272  138 
31  96  46,651  137 
Mean SI  13.2  17.5 
(SD)  (6.0)  (7.8) 
P value  0.025 > P > 0.01 
Mean SI* 
(SD) 
P value 
cpm  C'control 
567  52 
2,392  90 
1,437  249 
NT  NT 
7,267*  257 
1,158  171 
9,135"  199 
10,718"  256 
NT  NT 
NT  NT 
2,772  36 
2,347*  940 
3,997"  820 
NT  NT 
17,351"  103 
NT  NT 
3,508*  182 
14,793"  320 
1.2*  1.4* 
(0.5)*  (1.2)* 
P>0.1 t 
3.5*  10.6" 
(1.4)*  (I 1.9)* 
0.025 > P > 0.01" 
~of  ~of 
cpm  C* control  cpm  C* control 
26,955  45  1,528  125 
9,614  148  1,619  148 
59,920  59  1,154  109 
24,726  80  2,450  78 
36,966  52  2,747  179 
13,744  43  1,183  61 
68,036  51  2,476  73 
NT  NT  1,585  305 
13.1  0.7  --  -- 
(7.7)  (0.3) 
0.025 > P >  0.Ol  P >  0.I 
31,984  80  1,659  98 
23,889  89  1,695  98 
15,407  23  1,435  128 
56,477  59  973  59 
37,978  77  1,456  363 
25.6  0.6  --  -- 
(16.9)  (0.2) 
0.05 > P >  0.025  P >  0A 
24,487  61  1,567  102 
27,351  43  4,046  35 
26,819  67  1,933  98 
14,993  123  1,062  360 
24,320  75  5,792  280 
13.8  0.7  --  -- 
(7.4)  (0.2) 
P<0.005  P>0.1 
The data are actual  counts per minute for the complement (C*) control, and percent of C* control when cells were treated with 3C10 and 
C*. The percent depletion was calculated  as described  in Materials  and Methods.  Mean stimulation index (SI) and standard deviation (SD) 
are shown for each group. NT, not tested.  For significance testing, the paired comparisons  t test was used. 
* Patients  that respond to BCG (see Table 11). 
t  Data for all BCG nonresponders. 
M. leprae  in OKT8-  cultures, but did restore proliferation in response to BCG 
in cultures depleted of OKT4  ÷ (helper) cells. This would suggest that the OKT4 + 
cells are the  main  source of endogenous IL-2 and  that the remaining  OKT4- 
OKT8 +  T  cells  can  proliferate  if IL-2  is  provided.  We  conclude  that  T  cell 
anergy  in  lepromatous  disease  cannot  be  reversed  by  removing  the  OKT8 ÷ 
suppressor subset. 
Discussion 
Specific hyporesponsiveness  of T  cells to M. leprae antigens is well documented 
in  lepromatous  leprosy.  It  is  manifested  as  diminished  skin  test  responses  to KAPLAN  ET  AL. 
TABLE  V 
Effect of Monocyte Depletion on the Production of lFN-'y in Response to Antigens 
925 
Patient number 
Units IFN-~, produced in response to: 
C* control  3C10 +  C* 
M. leprae  BCG  No Ag  M. leprae  BCG  No Ag 
Nonresponders 
1  3.0  NT  2.0  3.0  NT  0.2 
2  3.8  3.5  3.5  5.0  15.0"  5.0 
6  0.3  5.6  0.3  3.8  74.5*  4.0 
7  3.0  3.0  2.8  7.5  1.5  4.0 
11  0.4  1.8  0.2  2.0  75.1"  0.1 
12  2.4  NT  2.4  3.5  NT  6.0 
Low responders 
18  2.4  NT  3.0  21.0  NT  1.8 
26  2.8  3.2  0.8  9.6  36.6*  2.0 
Responders 
28  5.2  3.0  0.8  9.0  4.0*  0.8 
30  15.2  4.8  0.2  20.0  35.8*  2.3 
31  68.5  19.7  0.2  68.4  180.0"  26.7 
Results are  expressed as  units IFN-7  produced.  Cells were  treated with complement only (C* 
control) or antimonocyte mAb and C* (3C10 +  C*). NT, not tested. No Ag, no antigen control. 
* Patients that respond to BCG (See Table II). 
TABLE  VI 
Effect of T Cell and Monocyte Depletion on the Proliferative Response to 
Antigen and Mitogen 
Treatment of cells 
Proliferative response (SI -_- SD) to: 
M, leprae 
(n =  9)  BCG (n =  2)  Con A (n =  7) 
C* control  1.3 +  0.5  14.3 ___ 7.6  20.0 _  13.7 
3C10 +  C*  1.4 +  1.1  13.9 _+ 8.2  9.4_+ 5.6 
OKT8 +  C*  1.4 +  1.4  6.6 _  4.2  10.5 _  4.8 
OKT4 +  C*  2.0 +  3.0  2.4 _  1.1  0.7 _  0.1 
3C10 +  OKT8 +  C*  1.3-+0.8  NT  17.3-+11.8 
Results are expressed as mean stimulation index ___ standard deviation. Cells were 
treated with complement only (C* control), antimonocyte mAb and C* (3C 10 + 
C*), antisuppressor T  cell mAb and C* (OKT8  +  C*), anti-helper T  cell mAb 
and C*  (OKT4  +  C*), and antimonocyte and suppressor T  cell mAb and C* 
(3C10  +  OKT8  +  C*).  NT,  not  tested.  The  range  of cpm  incorporated  in 
response to M. leprae was 500-4,800. The patients tested (not included in Table 
I) were all nonresponder LL with 0-14 yr of treatment. Results for BCG include 
only the two patients that responded to the antigen. Two patients were not tested 
for Con A. 
lepromin  antigens  as well as an  absence  of T  cell  proliferation  and  lymphokine 
release  in  vitro  (8,  9,  11,  12).  However,  patients  exhibit  responsiveness  to 
mitogenic  lectins  and  to  the  M.  leprae-related  organism,  BCG,  irrespective  of 
their  ability to respond  to M.  leprae.  Recent  observations  have  raised  the  possi- 
bility that M. leprae-specific sensitized  T  cells are present  in lepromatous  disease, 926  IN  VITRO  T  CELL  RESPONSIVENESS  IN  LEPROMATOUS  LEPROSY 
but that their function is compromised by inadequate  release of IL-2 (10) and/ 
or suppressor T  lymphocytes (15,  16,  18) or macrophages (19-21). 
Our  findings  in a  substantial  number of lepromatous patients  from  Bogota, 
Colombia and New York help clarify the deficiency in the cell-mediated immune 
response.  Peripheral  blood  T  cells  from  patients  with  lepromatous  leprosy 
proliferate and release IFN-~, to varying degrees in response to M. leprae antigens 
in vitro (Tables II and III). We noted that patients who were judged to be at the 
lepromatous pole by histopathologic  and clinical  criteria,  actually fell into two 
groups.  Approximately  half  were  unable  to  generate  a  detectable  response 
(nonresponders)  and  half were hyporesponders.  T  ceils from  the  latter  group 
exhibited a 6.1 _+ 2.9-fold boost in proliferation in response to M. leprae challenge 
and, in some cases, in IFN-~" release. It is this latter group in which some success 
has been achieved in enhancing the response to M. leprae in vitro. 
Experiments  in  which  specific cell  populations  were depleted indicated  that 
monocytes or their products, but not OKT8 + T  cells, could depress the thymidine 
incorporation  of T  cells in response to M. leprae  (Tables IV, V, and VI). This, 
however, was obtained only in responsive populations (hypo- and high respond- 
ers),  whereas  cells  from  unresponsive  patients  were  unaffected.  Therefore, 
monocyte  suppressor  activity  could  not  alone  explain  the  anergic  state.  In 
addition,  monocyte suppression was not limited to M. leprae,  as it was observed 
in the response to BCG. 
Studies from our laboratory (8) and those of others (10, 27, 28) have attempted 
to elucidate the capacity of IL-2 to reverse the unresponsiveness of T  cells from 
patients with iepromatous leprosy. In the present study this parameter has been 
studied with an  appreciation  of the  variable responses of lepromatous  leprosy 
patients to M. leprae.  The presence of exogenous IL-2 in cultures of cells from 
hyporesponsive patients enhances the M. leprae  proliferation and IFN-~, release 
by these cells. Since IL-2 did not induce specific T  cell function in the majority 
of M.  leprae  nonresponders,  and because the stimulation of hyporesponders by 
M. leprae in the presence of IL-2 and in its absence were similar (about fourfold, 
Fig. 2), we conclude that the IL-2 supplement did not lead to de novo sensitiza- 
tion, but instead appeared to expand already sensitized cells. These facts suggest 
that  the  absence of IL-2  production  per  se is  not responsible  for  the  anergic 
state.  Our results conflict with the reports that responsiveness is restored after 
exposure of the cells to exogenous IL-2 (10, 28). The discrepancy between our 
results and those of Haregewoin et al. (10) might be attributed to the heteroge- 
neity of responsiveness of the lepromatous patients.  Attempts to restore respon- 
siveness  with  exogenous  IL-2  would  appear  to  be  successful  if many  of the 
patients tested are low responders rather than nonresponders. 
Although M. leprae are sequestered within phagolysosomes of dermal macro- 
phages  and  Schwann  cells,  it  is  evident  that  antigen  is  gaining  access to  the 
immune system. Specifically, there are high levels of anti-M,  leprae antibodies in 
lepromatous disease (31). The immunoglobulins are primarily of the IgM subclass 
and therefore are likely to be to T  cell-independent antigenic determinants.  It 
is not known if the M. leprae determinants  that are required for effective T  cell 
stimulation are also accessible to the immune system. Both specific and nonspe- 
cific suppressor mechanisms could be operative within the infected dermis that KAPLAN ET  AL.  927 
might  block sensitization.  For  example,  recent  evidence  suggests a M.  leprae 
antigen,  the phenolic glycolipid I, specifically suppresses T  cell proliferation  in 
response to Con A in lepromatous patients (16). Unfortunately, current in vitro 
methodology  monitors  previously  sensitized  T  cell  function  rather  than  the 
priming  stage  of cell-mediated  immunity.  These  experiments  do not  provide 
information  on the capacity to prime cells in nonresponder  patients relative to 
responders. There is intriguing data that sensitization to antigens other than M. 
leprae is not effective in lepromatous disease (32, 33), and we are pursuing this 
in  current  clinical  trials.  There  are also genetic studies indicating  that  certain 
HLA  phenotypes  (DQ1)  predispose  individuals  to  the  nonresponsiveness  ob- 
served in  iepromatous  disease (34).  Many of these  considerations  can  now be 
approached experimentally, and their elucidation should enrich our knowledge 
of cell-mediated immunity in man. 
Summary 
In lepromatous leprosy, there is extensive replication of Mycobacterium leprae 
(M.  leprae)  within  dermal  macrophages.  This  lack  of microbial  resistance  has 
been  attributed  to  a  defective  cell-mediated  immune  response  to  M.  leprae 
antigens.  We  have  examined  the  in  vitro  response  of T  cells to M.  leprae  to 
determine  if  hyporesponsiveness  could  be  reversed.  The  study  included  40 
unselected patients  from  New York and from  Colombia, most with the severe 
lepromatous form of the disease. 
We  first  noted  that  lepromatous  leprosy patients  were  of two  types:  those 
unable  to  respond,  as  assessed  by T  cell  proliferation  and  immune  (gamma) 
interferon  (IFN--y) release,  and  a  second group,  exhibiting  low but detectable 
responses relative to tuberculoid controls. When the effect of exogenous recom- 
binant interleukin-2  (IL-2) on the response to M. leprae antigens was compared 
in  the  two groups,  many  of the  low  responders,  but  not  the  nonresponders, 
showed enhanced  proliferation  and  IFN-3, release.  To evaluate a  possible sup- 
pressive  effect  of monocytes,  these  cells  were  eliminated  with  a  cell-specific 
monoclonal antibody and complement. Depletion of monocytes often expanded 
preexisting  weak  responses  but  did  not  reverse  the  anergy  of the  M.  leprae 
nonresponders.  The enhancement  was not M.  leprae-specific,  since it was also 
observed when bacillus Calmette-Guerin was the antigenic stimulus for prolifer- 
ation  and  IFN-~,  production.  Removal  of the  suppressor  T  cell  subset,  with 
OKT8 antibody and complement, also did not restore responses in nonresponder 
patients.  We conclude  that  a  sizable  number  of iepromatous  leprosy patients 
exhibit a low degree of responsiveness to M. leprae and that the responses can be 
enhanced  in  vitro  with  IL-2  or  with  monocyte depletion.  Nonresponsiveness, 
however, cannot be reversed. Since currently available assays measure the func- 
tion of previously sensitized T  cells, suppressor mechanisms may yet contribute 
to defective cell-mediated immunity by impairing  the initial  sensitization  to M. 
leprae antigens. 
We wish to thank Dr. Ellen Pure for her helpful discussions of the manuscript,  Dr. Bernt 
Nesje for statistical analysis, and Ms. Linda Rubano for preparation of the manuscript. 
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